Skip to content
MPN Advocates Network
  • MPN Horizons
    • MPN Horizons 2022 Hybrid Conference
    • MPN Horizons Virtual Conference 2021: Learn. Share. Grow.
    • MPN Horizons 2021
    • MPN Horizons 2020 – Day 1
    • MPN Horizons 2020 – Day 2
    • MPN Horizons 2019
    • MPN Horizons 2018
    • MPN Horizons 2017
    • MPN Horizons 2016
  • About
  • Goal
  • Members
    • Members
    • Forum
  • In the News
  • Events
  • Info
    • What are MPN’s
    • Prevalence
    • Clinical trials
  • Contact

Inrebic, a new inhibitor drug for PMF, was approved by the EMA

13 January 2021 By Natasa Hace Comment Closed

Inrebic (fedratinib), a new inhibitor drug, received a positive opinion for the treatment of primary myelofibrosis and of myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia by the European Medicines Agency’s (EMA) Human Medicines Committee (CHMP) at its December 2020 meeting.
Please read more: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/inrebic

Geen categorie, In the News
Site Map

Home
MPN Horizons
About us
Goal
Members
In the News
Events
Info
Contact

CONTACT

MPN Advocates Network
c/o Münzgraben 6, P.O.B. 453,
CH-3000 Bern 7,
Switzerland
info@mpn-advocates.net

Search
WordPress Theme | Square by HashThemes